AR083575A1 - Aminopirazoles para inhibir la proteinquinasa chk1 - Google Patents

Aminopirazoles para inhibir la proteinquinasa chk1

Info

Publication number
AR083575A1
AR083575A1 ARP110103973A ARP110103973A AR083575A1 AR 083575 A1 AR083575 A1 AR 083575A1 AR P110103973 A ARP110103973 A AR P110103973A AR P110103973 A ARP110103973 A AR P110103973A AR 083575 A1 AR083575 A1 AR 083575A1
Authority
AR
Argentina
Prior art keywords
proteinquinase
aminopirazols
chk1
inhibit
hemioxalate
Prior art date
Application number
ARP110103973A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR083575A1 publication Critical patent/AR083575A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08Acetic acid
    • C07C53/10Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/06Oxalic acid
    • C07C55/07Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP110103973A 2010-11-08 2011-10-27 Aminopirazoles para inhibir la proteinquinasa chk1 AR083575A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41113710P 2010-11-08 2010-11-08

Publications (1)

Publication Number Publication Date
AR083575A1 true AR083575A1 (es) 2013-03-06

Family

ID=45044707

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103973A AR083575A1 (es) 2010-11-08 2011-10-27 Aminopirazoles para inhibir la proteinquinasa chk1

Country Status (22)

Country Link
US (1) US9067920B2 (https=)
EP (1) EP2638033B1 (https=)
JP (1) JP5792316B2 (https=)
KR (1) KR101533166B1 (https=)
CN (1) CN103180311B (https=)
AR (1) AR083575A1 (https=)
AU (1) AU2011326230B2 (https=)
BR (1) BR112013010009B1 (https=)
CA (1) CA2816944C (https=)
DK (1) DK2638033T3 (https=)
EA (1) EA022096B1 (https=)
ES (1) ES2541414T3 (https=)
HR (1) HRP20150530T1 (https=)
JO (1) JO3145B1 (https=)
ME (1) ME02119B (https=)
MX (1) MX2013005181A (https=)
PL (1) PL2638033T3 (https=)
PT (1) PT2638033E (https=)
RS (1) RS54012B1 (https=)
SI (1) SI2638033T1 (https=)
TW (1) TWI501956B (https=)
WO (1) WO2012064548A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
HRP20220351T1 (hr) 2016-02-04 2022-05-13 Pharmaengine, Inc. 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
AU2021389190A1 (en) 2020-11-30 2023-06-29 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1h-pyrazol-3-amine derivative
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
US11932648B2 (en) 2021-06-28 2024-03-19 Blueprint Medicines Corporation CDK2 inhibitors
US20250129049A1 (en) * 2021-12-24 2025-04-24 Sumitomo Pharma Co., Ltd. 1h-pyrazole-3-amine derivative having bicyclic backbone
US20250352541A1 (en) * 2022-05-27 2025-11-20 Sumitomo Pharma Co., Ltd. Therapeutic for cancer refractory to immune checkpoint inhibitor
TW202442234A (zh) * 2023-04-14 2024-11-01 美商纜圖藥品公司 Cdk2抑制劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000933A (es) * 2003-07-25 2006-03-30 Pfizer Compuestos de aminopirazol y uso como inhibidores de chk1.
BRPI0418351A (pt) * 2004-01-05 2007-05-08 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
EA011671B1 (ru) 2004-06-04 2009-04-28 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
CN101218229A (zh) * 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
AU2006258101A1 (en) * 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1

Also Published As

Publication number Publication date
AU2011326230A1 (en) 2013-05-09
EP2638033A1 (en) 2013-09-18
JP5792316B2 (ja) 2015-10-07
EA201390499A1 (ru) 2013-08-30
CA2816944C (en) 2015-12-22
KR101533166B1 (ko) 2015-07-01
BR112013010009B1 (pt) 2021-10-19
CN103180311A (zh) 2013-06-26
DK2638033T3 (en) 2015-04-27
BR112013010009A2 (pt) 2020-09-29
PT2638033E (pt) 2015-06-01
JO3145B1 (ar) 2017-09-20
EP2638033B1 (en) 2015-04-08
CA2816944A1 (en) 2012-05-18
TWI501956B (zh) 2015-10-01
CN103180311B (zh) 2014-08-20
JP2013541586A (ja) 2013-11-14
ME02119B (me) 2015-10-20
US20130190262A1 (en) 2013-07-25
HRP20150530T1 (hr) 2015-06-19
US9067920B2 (en) 2015-06-30
WO2012064548A1 (en) 2012-05-18
EA022096B1 (ru) 2015-10-30
RS54012B1 (sr) 2015-10-30
PL2638033T3 (pl) 2015-09-30
ES2541414T3 (es) 2015-07-20
KR20130099146A (ko) 2013-09-05
SI2638033T1 (sl) 2015-05-29
AU2011326230B2 (en) 2015-02-19
TW201305138A (zh) 2013-02-01
MX2013005181A (es) 2013-10-17

Similar Documents

Publication Publication Date Title
AR083575A1 (es) Aminopirazoles para inhibir la proteinquinasa chk1
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
CO6382125A2 (es) Inhibidores de proteína quinasa
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
PE20141038A1 (es) Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
EA201490759A1 (ru) Ингибиторы протеинкиназы
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
ES2691742T3 (es) Tratamiento de cánceres utilizando moduladores de isoformas de PI3 cinasa
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
AR085668A1 (es) Terapias combinadas para malignidades hematologicas
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CL2016000816A1 (es) Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras.
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
WO2012141796A3 (en) Prostate cancer therapy with hsp90 inhibitory compounds
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
CO6361991A2 (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.
PE20121523A1 (es) Metodo de tratamiento
MX2016004967A (es) Tratamiento para cancer pancreatico.
PH12013500545A1 (en) Oxadiazole inhibitors of leukotriene production

Legal Events

Date Code Title Description
FG Grant, registration